iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

iMDx will highlight its GraftAssure technology at the American Transplant Congress in Boston, showcasing favorable third-party head-to-head data comparing its assay to leading commercial tests. The company will announce winners of a research grant sponsored jointly with the American Society of Transplant Surgeons to evaluate the economics of in-house versus centralized transplant rejection testing.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.